New Research on Emerging Cutaneous Lupus Erythematosus (CLE) Market Reveals Vast Potential for Pipeline Agents, According to Spherix Global Insights
EXTON, Pa., May 8, 2023 /PRNewswire/ -- According to the Lupus Foundation of America, approximately two-thirds of people with the autoimmune condition systemic lupus erythematosus (SLE) will develop some type of skin disease, called cutaneous lupus erythematosus (CLE). Skin disease in lupus can cause rashes or lesions, most of which will appear on the sun-exposed areas of the body.
- EXTON, Pa., May 8, 2023 /PRNewswire/ -- According to the Lupus Foundation of America , approximately two-thirds of people with the autoimmune condition systemic lupus erythematosus (SLE) will develop some type of skin disease, called cutaneous lupus erythematosus (CLE).
- Skin disease in lupus can cause rashes or lesions, most of which will appear on the sun-exposed areas of the body.
- – Rheumatologist
There are currently no specific FDA-approved therapies for cutaneous lupus erythematosus (CLE) or discoid lupus erythematosus (DLE) – conditions which mostly affect women and people of color. - Spherix Global Insight's Market Dynamix™ Cutaneous Lupus Erythematosus service focuses on this evolving market, where a paradigm shift is expected within the next few years.